Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Didcot, OX, GB. The stock last traded at $0.56, down 3.34% on the session, giving a market capitalisation of $22.7M. On trailing twelve-month figures it carries a trailing P/E of -0.54, a net margin of 0.0%. Its beta of -0.38 implies it has historically moved less than the broad market.
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Barinthus Biotherapeutics plc is most often compared with the following Healthcare names: